Table 1 Summary of included trials basic information
Study ID | Settings | Recruit Sources | TG (M/F) | CG (M/F) | Age (mean or range) | Disease history (mean or range) | Diagnostic criteria (angina type) | AE |
|---|---|---|---|---|---|---|---|---|
BALLEGAARD 1986 [35] | Denmark | NR | 12/1 | 11/2 | TG: 54; CG: 58 | NR | Modified WHO/ISFC (SAP) | NO |
BALLEGAARD 1990 [36] | Denmark | News | 19/5 | 19/6 | TG: 67; CG: 66 | NR | Modified WHO/ISFC (SAP) | NO |
CAO JP 2002 [41] | MC | In | 7/23 | 5/16 | TG: 63; CG: 63 | TG: 55.14Â m; CG: 61.62Â m | WHO/ISFC, IM 4th (UAP) | NR |
CHANG PF 2005 [42] | MC | Out | 19/11 | 17/5 | TG: 59; CG: 61 | TG:6.4y; CG:7.2y | WHO/ISFC, PIM (SAP) | NR |
DIAO LH 2006 [43] | MC | NR | 8/22 | 6/24 | TG: 57; CG: 57 | NR | WHO/ISFC, GCC, PIM (SAP) | NR |
MC | NR | 9/21 | 6/24 | TG: 57; CG: 57 | NR | NR | ||
HU NK 1997 [44] | MC | In | 60 | 60 | 59 | NR | WHO/ISFC (CHD-AP) | NR |
HUANG J 2004 [45] | MC | Out | 22/18 | 21/19 | TG:56; CG:57 | TG: 5.3y; CG: 5.2y | WHO/ISFC (SAP) | NO |
HUANG J2 2004 [46] | MC | Out/In | 11/9 | 7/13 | TG: 60; CG: 59 | NR | WHO/ISFC, PIM (SAP) | NR |
MC | Out/In | 7/13 | 7/13 | TG: 60; CG: 59 | NR | NR | ||
LI CP 2005 [47] | MC | Out/In | 36 | 34 | 64 | 3.82y | WHO/ISFC (CHD-AP) | NR |
LI HJ 2003 [48] | MC | NR | 19/17 | 16/13 | TG: 57; CG: 55 | TG: 8y; CG: 7.5y | WHO/ISFC (CHD-AP) | NR |
LIU JL 2007 [49] | MC | In | 20/10 | 21/9 | TG: 57; CG: 57 | TG: 9.2y; CG: 8.5y | GCC (UAP) | NR |
LIU JR 2010 [50] | MC | Out/In | 18/12 | 19/13 | TG: 49; CG: 49 | TG: 6.6y; CG: 6.5y | GCC (CHD-AP) | NR |
LIU WP 2004 [51] | MC | In | 26/6 | 25/5 | TG: 58; CG: 57 | TG: 24.8Â m CG: 24.5Â m | WHO/ISFC (UAP) | NR |
LIU WP 2003 [52] | MC | Out/In | 19/13 | 19/12 | TG: 58; CG: NR | TG: 24.8Â m; CG: 20.6Â m | WHO/ISFC (SAP) | NR |
LIU YF 2012 [53] | MC | Out/In | 18/15 | 17/16 | TG: 66; CG: 65 | 6Â m-15y | 2007ACC/AHA (SAP) | NR |
TONG YH 2005 [54] | MC | In | 42/38 | 37/23 | TG: 61; CG: 60 | TG: 2Â m-3.5y; CG: 3Â m-3y | WHO/ISFC (CHD-AP) | NR |
WANG PJ 2011 [55] | MC | In | 30 | 30 | 53 | 2-10y | Modified GCC (SAP) | NR |
MC | In | 30 | 30 | 53 | 2-10y | NR | ||
WANG X 2000 [56] | MC | NR | 18/10 | 14/7 | TG: 57; CG: 53 | NR | WHO/ISFC (UAP) | NR |
WU CY 2009 [57] | MC | Out/In | 39/29 | 40/28 | TG: 48; CG: 48 | TG: 26.4Â m; CG: 25.6Â m | WHO/ISFC (CHD-AP) | NR |
WU HH 2005 [58] | MC | In | 23/17 | 19/21 | NR | NR | WHO/ISFC (CHD-AP) | NR |
XIE ZQ 2003 [59] | MC | In | 15/16 | 26/10 | TG: 61; CG: 60 | NR | Modified GCC (UAP) | NR |
MC | In | 68/52 | 47/33 | TG: 63; CG: 63 | TG: 23Â m; CG: 2.4Â m | WHO/ISFC (CHD-AP) | NR | |
YU W 2006 [62] | MC | In | 17/13 | 15/15 | TG: 67; CG: 66 | TG: 8.35y; CG: 8.71y | WHO/ISFC (CHD-AP) | NO |
ZHANG L 2011 [63] | MC | NR | 19/16 | 17/13 | TG: 62; CG: 61 | TG: 6.70y; CG: 6.52y | WHO/ISFC (CHD-AP) | NR |
ZHANG LJ 2005 [64] | MC | Out/In | 18/22 | 25/15 | TG: 43–70; CG: 43-69 | TG: 5 m-20y; CG:2 m-19y. | WHO/ISFC, GCC (CHD-AP) | NR |
MC | Out/In | 21/19 | 25/15 | TG: 45–72; CG: 43-69 | TG: 6 m-24y;CG: 2 m-19y. | NR |